HRP20240823T1 - Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 - Google Patents
Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 Download PDFInfo
- Publication number
- HRP20240823T1 HRP20240823T1 HRP20240823TT HRP20240823T HRP20240823T1 HR P20240823 T1 HRP20240823 T1 HR P20240823T1 HR P20240823T T HRP20240823T T HR P20240823TT HR P20240823 T HRP20240823 T HR P20240823T HR P20240823 T1 HRP20240823 T1 HR P20240823T1
- Authority
- HR
- Croatia
- Prior art keywords
- phase
- subcutaneous
- pharmaceutical preparation
- administration
- dose
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 208000022401 dense deposit disease Diseases 0.000 claims 2
- 231100000562 fetal loss Toxicity 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (2)
1. Farmaceutski pripravak, formuliran za supkutanu injekciju koja sadrži protutijelo protiv C5, koji sadrži VH slijed SEQ ID NO: 2 i VL slijed SEQ ID NO: 6, naznačen time što je namijenjen upotrebi u postupku liječenja ili sprječavanja bolesti povezane s C5, koju se bira iz skupine koju čine reumatoidni artritis (RA); lupozni nefritis; ishemijsko-reperfuzijska ozljeda; paroksiumalna noćna hemoglobinurija (PNH), atipični hemolitički uremijski sindrom (aHUS), bolest gustih naslaga (DDD); degeneracija makule; hemoliza, povišeni jetreni enzimi, te sindrom niskih trombocita (HELLP); trombotska trombocitopenična purpura (UP); spontani gubitak fetusa; oligoimuni vaskulitis; bulozna epidermoliza; recidivirajući gubitak fetusa; multipla skleroza (MS); traumatska ozljeda mozga; ozljeda koja je posljedica infarkta miokarda, kardiopulmonalna premosnica ili hemodijaliza; refraktorna generalizirana miastenija gravis (gMG), te neuromijelitis očnog živca (NMO),
gdje se pripravak supkutano primijenjuje u dvije faze nakon primjene farmaceutskog pripravka formuliranog za intravensku injekciju koja sadrži protutijelo protiv C5,
gdje u obje faze supkutanih primjena postoji interval između svake dvije supkutane primjene,
gdje svaka faza sadrži najmanje jedan interval,
gdje je doza protutijela intravenske primjene 1000 mg,
gdje se prvu supkutanu primjenu prve faze primijenjuje 0 do 8 dana nakon konačne primjene intravenski primijenjenog farmaceutskog pripravka,
gdje je doza protutijela u supkutanoj primjeni prve faze 170 mg ili 340 mg,
gdje se farmaceutski pripravak primijenjuje u prvoj fazi jednom svakog tjedna (tjedno), te
gdje se farmaceutski pripravak namijenjen supkutana primjena primijenjuje u drugoj fazi četiri puta tjedno, u dozi od 680 mg.
2. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je broj supkutanih primjena u prvoj fazi 1 do 12.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713211P | 2018-08-01 | 2018-08-01 | |
US201862764952P | 2018-08-17 | 2018-08-17 | |
US201862760204P | 2018-11-13 | 2018-11-13 | |
PCT/JP2019/030283 WO2020027279A1 (en) | 2018-08-01 | 2019-08-01 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
EP19755447.0A EP3829628B1 (en) | 2018-08-01 | 2019-08-01 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240823T1 true HRP20240823T1 (hr) | 2024-09-27 |
Family
ID=67660420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240823TT HRP20240823T1 (hr) | 2018-08-01 | 2019-08-01 | Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20210301004A1 (hr) |
EP (2) | EP3829628B1 (hr) |
JP (3) | JP6672516B2 (hr) |
KR (5) | KR20200033225A (hr) |
CN (1) | CN112512563A (hr) |
AU (2) | AU2019315213B2 (hr) |
BR (1) | BR112021001655A2 (hr) |
CA (1) | CA3107618A1 (hr) |
CR (1) | CR20210103A (hr) |
DE (1) | DE112019003835T5 (hr) |
ES (1) | ES2980137T3 (hr) |
HR (1) | HRP20240823T1 (hr) |
HU (1) | HUE067057T2 (hr) |
IL (1) | IL280475A (hr) |
MX (1) | MX2021000516A (hr) |
PH (1) | PH12021550226A1 (hr) |
PL (1) | PL3829628T3 (hr) |
RS (1) | RS65630B1 (hr) |
SG (1) | SG10202002898RA (hr) |
TW (2) | TWI704157B (hr) |
WO (1) | WO2020027279A1 (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
RU2746356C2 (ru) | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2483991T3 (es) | 2000-10-10 | 2014-08-08 | Genentech, Inc. | Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II |
EP1425042B2 (en) | 2001-08-17 | 2016-02-10 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-p-셀렉틴 항체 |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
SI2328616T1 (sl) | 2008-08-05 | 2015-08-31 | Novartis Ag | Sestavki in postopki za protitelesa proti komplementnemu proteinu C5 |
HRP20230167T1 (hr) | 2008-11-10 | 2023-03-31 | Alexion Pharmaceuticals, Inc. | Postupci i pripravci za liječenje poremećaja povezanih s komplementom |
BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
US10280215B2 (en) * | 2013-01-31 | 2019-05-07 | Seoul National University R&Db Foundation | Anti-C5 antibodies and methods of treating complement-related diseases |
RU2746356C2 (ru) * | 2014-12-19 | 2021-04-12 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
CA2972393A1 (en) * | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
WO2017123636A1 (en) * | 2016-01-11 | 2017-07-20 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
WO2017132259A1 (en) | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
SG11202005181RA (en) * | 2017-12-04 | 2020-07-29 | Ra Pharmaceuticals Inc | Modulators of complement activity |
-
2019
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en active Application Filing
- 2019-08-01 PL PL19755447.0T patent/PL3829628T3/pl unknown
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko active Application Filing
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active IP Right Cessation
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 HR HRP20240823TT patent/HRP20240823T1/hr unknown
- 2019-08-01 KR KR1020247023205A patent/KR20240115904A/ko active Search and Examination
- 2019-08-01 EP EP24174873.0A patent/EP4445913A2/en active Pending
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 RS RS20240695A patent/RS65630B1/sr unknown
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active IP Right Cessation
- 2019-08-01 HU HUE19755447A patent/HUE067057T2/hu unknown
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 ES ES19755447T patent/ES2980137T3/es active Active
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko active Application Filing
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-28 IL IL280475A patent/IL280475A/en unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
-
2024
- 2024-08-02 AU AU2024205486A patent/AU2024205486A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240823T1 (hr) | Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5 | |
JP2018141025A5 (hr) | ||
JP2020019769A5 (hr) | ||
Yuri Gasparyan et al. | Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research | |
Vivar et al. | Advances in the treatment of rheumatoid arthritis | |
Villablanca et al. | Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases | |
DK1988882T3 (en) | PROLONGED SURVIVAL OF A allograft by inhibiting complement activity | |
Spear et al. | NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors | |
KR102365871B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
HRP20231063T1 (hr) | Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha | |
EP3344772B1 (en) | Antagonistic pdl1 aptamers and their applications in cancer therapy | |
JP2018520094A5 (hr) | ||
KR102321372B1 (ko) | 인터류킨-6에 대한 항체 및 그의 용도 | |
CN101939025A (zh) | 搔痒症治疗药 | |
EP3349798A1 (en) | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor | |
TaŞKapilioĞLu | Recent advances in the treatment for multiple sclerosis; current new drugs specific for multiple sclerosis | |
KR20160079918A (ko) | Vegf 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
RU2023101857A (ru) | Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания | |
JP2022104920A5 (hr) | ||
Bai et al. | Biological therapies of inflammatory bowel disease | |
RU2021104477A (ru) | Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с с5 заболевания, и способ лечения или предупреждения связанного с с5 заболевания | |
JP2022101535A5 (hr) | ||
EP3280732B1 (en) | Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases | |
KR20170055473A (ko) | 길항 ctla-4 압타머 및 면역 활성의 증진에서의 그의 적용 | |
Lang et al. | High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults |